Amgen Inc. (AMGN) earnings on April 30, 2026
Prior outlook: Pessimistic Outcome: Accurate
The stock dropped nearly 5% after its earnings release disappointed investors.
AMGN price around the earnings
329.80
Change: -4.7%
2026-05-01, 19:59 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Pessimistic Outcome: Accurate
- Thesis published
Analysts cautious, limited upside before earnings.
Experts note that while the company has a history of strong earnings, current price trends and analyst expectations suggest limited upside potential before the next earnings report.
Context analyzed before publication
- Summary
- Analysts cautious, limited optimistic scenario before earnings.
- Reasoning
- Experts note that while the company has a history of strong earnings, current price trends and analyst expectations suggest a limited optimistic scenario before the next earnings report.
- Playbook
- Given the weak momentum and cautious analyst outlook, the scenario suggests waiting for a clearer context before considering new positions.
- Trend
- Outlook deteriorating over past two sessions.
Analysts
Drivers
-
Analysts
Neutral
Most analysts rate the stock as 'Hold' and do not expect a significant optimistic scenario, with few new positive developments anticipated.
Evidence
- Analyst consensus
- Hold
- Consensus average (1-5)
- 2.51
- Analysts covering the stock
- 30
- Average price target
- 352.73
- Lowest price target
- 200
- Highest price target
- 432
- Upside to price target
- 2.3%
- Quarterly earnings growth
- 112.6%
- Revenue growth
- 8.6%
- Forward EPS
- 23.31
- Trailing EPS
- 14.24
- Analyst moves in the last 60 days
- 6
- Strong buy: 4
- Buy: 9
- Hold: 19
- Sell: 2
- Strong sell: 1
- Strong buy
- 4
- Buy
- 9
- Hold
- 19
- Sell
- 2
- Strong sell
- 1
- April 21, 2026 · Canaccord Genuity: Initiates coverage (Hold)
- April 13, 2026 · UBS: Maintains rating (Buy → Buy)
- April 10, 2026 · Morgan Stanley: Maintains rating (Equal-Weight → Equal-Weight)
- April 9, 2026 · Guggenheim: Maintains rating (Neutral → Neutral)
- April 8, 2026 · Cantor Fitzgerald: Reiterates rating (Neutral → Neutral)
- March 10, 2026 · Jefferies: Initiates coverage (Hold)
News and sentiment
Drivers
-
News & sentiment
Negative
Although the stock has declined, individual investors are showing very strong optimism, which is contrary to the price trend.
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (9)
- Canaccord Genuity Initiates Coverage On Amgen with Hold Rating, Announces Price Target of $366 — Benzinga
- $1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today — Benzinga
- UBS Maintains Buy on Amgen, Raises Price Target to $400 — Benzinga
- Guggenheim Maintains Neutral on Amgen, Raises Price Target to $351 — Benzinga
- Cantor Fitzgerald Reiterates Neutral on Amgen, Maintains $350 Price Target — Benzinga
- Why Is Viridian Therapeutics Stock Sinking Monday? — Benzinga
- Amgen Posts 77% Response In Thyroid Eye Disease Study — Benzinga
- Amgen Announces Phase 3 Study Of TEPEZZA Meets Primary Endpoint In Moderate-To-Severe Active Thyroid Eye Disease; Demonstrates 77% Proptosis Response Rate — Benzinga
- If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today — Benzinga
Technicals
Drivers
-
Technical
Negative
The stock's price movement has weakened significantly over the last month, and it has performed much worse than the broader market.
Evidence
- Average true range (ATR)
- 2.1%
- Distance to 52-week high
- -11.9%
- 14-day change (14d)
- -2.4%
- 30-day change
- -8.3%
- 30-day relative strength
- -12.0%
- Benchmark change
- +3.8%
- Nearest support
- 335.06
- Nearest resistance
- 379.75
- Volume accumulation ratio
- 0.96
Trends
Drivers
-
Macro & trends
Positive
Historically, the company has consistently exceeded earnings expectations, often by a large margin.
Evidence
- Average earnings surprise
- +32.4%
- February 3, 2026: actual EPS 2.45 vs estimate 2.41 (surprise +1.5%)
- November 4, 2025: actual EPS 5.93 vs estimate 2.6 (surprise +128.1%)
- August 5, 2025: actual EPS 2.65 vs estimate 3.12 (surprise -15.1%)
- May 1, 2025: actual EPS 4.9 vs estimate 4.26 (surprise +15.0%)
Expected move
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 4.8%
- 75th percentile move
- 6.5%
- 90th percentile move
- 7.9%
- Up / down moves
- 9 / 10
- Average up move
- +5.8%
- Average down move
- -3.4%
Monitoring and close
What Amgen Inc. reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- -4.7%
- Max favorable move (MFE)
- 6.2%
- Max adverse move (MAE)
- 0%